Three EU GMP Changes in 21 Days: Inspection Coordination, Annex 19 and PI 006-4

For Canadian sites that manufacture for the European market, or that hope to, the autumn of 2026 is unusually busy. Three separate good manufacturing practice changes take effect within twenty-one days of each other. The European Medicines Agency's procedure for coordinating inspections of centrally authorised products moved to version 3 on 10 September 2026. A revised EU GMP Annex 19, on reference and retention samples, becomes applicable on 24 September 2026. And the PIC/S recommendations on qualification and validation, PI 006-4, come into force on 1 October 2026. Individually, each is manageable. Together, they reshape how European inspections are run, how retention samples are held, and how validation is documented, all in three weeks.

The 1 October date is shared with a cluster of Canadian instruments too, including the SOR/2025-244 Cannabis Regulations changes, so quality and regulatory teams face a genuinely crowded calendar. This article focuses on the three EU and PIC/S GMP changes, what each one does, how they connect, and the practical steps a Canadian organization should take.

Executive summary

The table below sets out the three changes, their effective dates and the teams most affected.

Change one: EMA inspection-coordination procedure, version 3

What it is: the EMA procedure titled Co-ordinating good manufacturing practice inspections for centrally authorised products, part of the Compilation of Union Procedures, moved to version 3 with an entry into force of 10 September 2026. It supersedes the previous version, which had been in force since 1 January 2025. Why it matters: the revision clarifies how inspections may be conducted without a separate supporting authority. In practice, a single authority may now act as both the leading and the supporting authority in defined situations, such as quality control laboratories, very small sites, and sites that have only one supervisory authority for centrally authorised products. It also reiterates that sites volunteering for a pre-approval inspection should be provided within a short window.

What to do: if your site is named on a centrally authorised product dossier, recognize that inspector pairing may be less predictable and notice periods may be shorter. Keep your Site Master File current, make sure your inspection-readiness programme does not depend on a long lead time, and confirm your host team can respond quickly if your site is selected. Canada has no mutual recognition agreement with the EU for medicinal products, so Canadian sites on a dossier sit inside the EMA's re-inspection programme and should plan accordingly.

Change two: revised Annex 19 on reference and retention samples

What it is: the European Commission adopted a revised Annex 19 of EudraLex Volume 4 under Commission Decision C(2026) 4135, and it becomes applicable on 24 September 2026. The revision focuses on reference and retention samples, with new provisions for parallel imported, parallel distributed and parallel traded products, clearer rules for re-packaging and packaging material retention, and a controlled allowance for photographic or digital records as an alternative to physical retention samples in defined circumstances. Why it matters: retention samples are a quiet area of GMP until an inspector asks to see them. The new rules raise expectations for sample governance, traceability and written agreements across the supply chain, particularly where products move through parallel trade. We covered the detail in our Why it matters: retention samples are a quiet area of GMP until an inspector asks to see them. The new rules raise expectations for sample governance, traceability and written agreements across the supply chain, particularly where products move through parallel trade. We covered the detail in our Why it matters: retention samples are a quiet area of GMP until an inspector asks to see them. The new rules raise expectations for sample governance, traceability and written agreements across the supply chain, particularly where products move through parallel trade. We covered the detail in our analysis of the revised Annex 19.

What to do: review your retention sample SOP against the revised Annex, confirm that written agreements with parallel traders and re-packagers define who holds which samples, and decide, with a documented rationale, whether and where you will use photographic or digital records rather than physical samples. Do not assume the digital allowance applies everywhere; it is conditional.

Change three: PIC/S PI 006-4 on qualification and validation

What it is: PIC/S PI 006-4, Recommendations on Qualification and Validation, comes into force on 1 October 2026 and supersedes PI 006-3. Where PI 006-3 was four separate recommendations covering the validation master plan, installation and operational qualification, non-sterile process validation and cleaning validation, PI 006-4 is a single consolidated document aligned with the 2015 revision of Annex 15, with quality risk management under ICH Q9 running through every section. Why it matters: the scope is broader than the old recommendations. PI 006-4 addresses prequalification stages, performance qualification, ongoing process verification, transport verification, packaging validation, utility qualification and test method validation. Health Canada participates in PIC/S, so the document informs inspection expectations for Canadian sites as well as European ones.

What to do: revisit your validation master plan so its structure reflects the consolidated, risk-based approach, and check that your cleaning validation programme and your process, packaging and method validation documents align with the new expectations. Pay particular attention to ongoing process verification and transport verification, which were not prominent in the older recommendations.

How the three changes connect

These are not three isolated documents. The inspection-coordination procedure changes who inspects and how, Annex 19 changes what they will expect to see in your retention-sample system, and PI 006-4 changes how your validation evidence should be structured. An inspector arriving at a Canadian site under the new coordination rules may well probe both retention samples and validation. That is why the smart response is a single, combined readiness review rather than three separate projects. The wider picture, including the other annexes and chapters being rewritten through 2028, is set out in our EU GMP guide revision roadmap.

Compliance checklist before 1 October 2026

• Confirm your Site Master File is current and your inspection-readiness programme does not rely on a long notice period.
• Identify every product dossier on which your site is named as a manufacturing location for a centrally authorised product.
• Update your reference and retention sample SOP against revised Annex 19, including parallel-trade and re-packaging scenarios.
• Document a rationale for where photographic or digital retention records will, and will not, replace physical samples.
• Restructure your validation master plan to match the consolidated, risk-based approach in PI 006-4.
• Check that ongoing process verification, transport verification, packaging validation, utility qualification and test method validation are all addressed.
• Confirm written quality agreements across the supply chain assign sample, validation and inspection responsibilities clearly.

Common mistakes to avoid

• Treating these as EU-only problems. With no EU mutual recognition agreement for medicinal products, Canadian sites are directly exposed, and PIC/S membership means PI 006-4 reaches domestic inspections too.
• Running three separate projects. The changes overlap at the point of inspection, so a combined readiness review is faster and less likely to leave gaps.
• Assuming digital retention samples are always allowed. The Annex 19 allowance for photographic or digital records is conditional and needs a documented justification.
• Leaving the validation master plan untouched. PI 006-4 is structurally different from PI 006-3, so a plan written to the old four-part model may not map cleanly to the new document.
• Relying on a stale Site Master File. Shorter, less predictable inspection notice makes an out-of-date Site Master File a real liability.

Frequently asked questions

When do the three EU GMP changes take effect?

The EMA inspection-coordination procedure version 3 entered into force on 10 September 2026, revised Annex 19 becomes applicable on 24 September 2026, and PIC/S PI 006-4 comes into force on 1 October 2026, a span of twenty-one days.

Do these changes apply to Canadian manufacturers?

Yes, where relevant. Canada has no mutual recognition agreement with the EU for medicinal products, so Canadian sites that supply the EU or appear on centrally authorised product dossiers are subject to EU inspection expectations. Health Canada participates in PIC/S, so PI 006-4 also informs domestic inspection expectations.

What changed in Annex 19?

The revised Annex 19, adopted under C(2026) 4135 and applicable 24 September 2026, updates reference and retention sample rules, with new provisions for parallel imported, distributed and traded products, clearer re-packaging and packaging material retention rules, and a conditional allowance for photographic or digital records instead of physical samples.

How is PI 006-4 different from PI 006-3?

PI 006-3 was four separate recommendations. PI 006-4 consolidates them into one document aligned with the 2015 Annex 15 revision, with quality risk management throughout, and adds prequalification, performance qualification, ongoing process verification, transport verification, packaging validation, utility qualification and test method validation.

What is the EMA inspection-coordination procedure?

It is the EMA procedure that coordinates GMP inspections of manufacturing sites tied to centrally authorised products. Version 3, in force from 10 September 2026, clarifies inspections conducted without a separate supporting authority and allows a single authority to act in both roles in defined cases.

Should we run one project or three?

One. The three changes meet at the point of inspection, so a single combined readiness review covering inspection preparedness, retention samples and validation is more efficient and less likely to leave a gap between workstreams.

How MFLRC can help

MF License & Regulatory Consultants helps Canadian pharmaceutical and cannabis manufacturers prepare for EU and PIC/S inspections. For this autumn's changes we run a combined readiness review covering inspection preparedness, retention samples and validation in one engagement. Our pharmaceutical validation services team can restructure your validation master plan and validation documents to PI 006-4, and our audit services team can run a mock EU inspection and refresh your Site Master File so you are ready if your site is selected.

Conclusion

Three GMP changes in twenty-one days is a tight window, but it is also an opportunity to get ahead. The organizations that handle it well will treat the inspection-coordination procedure, Annex 19 and PI 006-4 as one connected readiness exercise, not three chores. If you manufacture for the European market from the pharmaceuticals sector, the time to act is now, before the dates pass rather than after an inspection finding.

Sources and references

• EMA: Co-ordinating GMP inspections for centrally authorised products (Compilation of Union Procedures)
• European Commission: EudraLex Volume 4, Annex 19 Reference and Retention Samples (applicable 24 September 2026)
• PIC/S news: Revision of PIC/S Recommendations on Qualification and Validation (PI 006-4), in force 1 October 2026
• European Commission: EudraLex Volume 4 Good Manufacturing Practice guidelines